Contents 1 Overview 2 Metrics 3 Pharmacokinetic models 3.1 Noncompartmental analysis 3.2 Compartmental analysis 3.3 Single-compartment model 3.4 Multi-compartmental models 3.5 Variable volume in time models 4 Bioavailability 5 LADME 6 Analysis 6.1 Bioanalytical methods 6.2 Mass spectrometry 7 Population pharmacokinetics 8 Clinical pharmacokinetics 9 Ecotoxicology 10 See also 11 References 12 External links 12.1 Software 12.2 Educational centres Overview[edit]
Liberation – the process of release of a drug from the
pharmaceutical formulation.[3][4] See also IVIVC.
Absorption – the process of a substance entering the blood
circulation.
Distribution – the dispersion or dissemination of substances
throughout the fluids and tissues of the body.
The two phases of metabolism and excretion can also be grouped together under the title elimination. The study of these distinct phases involves the use and manipulation of basic concepts in order to understand the process dynamics. For this reason in order to fully comprehend the kinetics of a drug it is necessary to have detailed knowledge of a number of factors such as: the properties of the substances that act as excipients, the characteristics of the appropriate biological membranes and the way that substances can cross them, or the characteristics of the enzyme reactions that inactivate the drug. All these concepts can be represented through mathematical formulas that have a corresponding graphical representation. The use of these models allows an understanding of the characteristics of a molecule, as well as how a particular drug will behave given information regarding some of its basic characteristics such as its acid dissociation constant (pKa), bioavailability and solubility, absorption capacity and distribution in the organism. The model outputs for a drug can be used in industry (for example, in calculating bioequivalence when designing generic drugs) or in the clinical application of pharmacokinetic concepts. Clinical pharmacokinetics provides many performance guidelines for effective and efficient use of drugs for human-health professionals and in veterinary medicine. Metrics[edit] The following are the most commonly measured pharmacokinetic metrics:[5] Characteristic Description Example value Symbol Formula Dose Amount of drug administered. 500 mg D displaystyle D Design parameter
τ displaystyle tau Design parameter Cmax The peak plasma concentration of a drug after administration. 60.9 mg/L C max displaystyle C_ text max Direct measurement tmax Time to reach Cmax. 3.9 h t max displaystyle t_ text max Direct measurement Cmin The lowest (trough) concentration that a drug reaches before the next dose is administered. 27.7 mg/L C min , ss displaystyle C_ text min , text ss Direct measurement Volume of distribution The apparent volume in which a drug is distributed (i.e., the parameter relating drug concentration in plasma to drug amount in the body). 6.0 L V d displaystyle V_ text d = D C 0 displaystyle = frac D C_ 0 Concentration Amount of drug in a given volume of plasma. 83.3 mg/L C 0 , C ss displaystyle C_ 0 ,C_ text ss = D V d displaystyle = frac D V_ text d Elimination half-life The time required for the concentration of the drug to reach half of its original value. 12 h t 1 2 displaystyle t_ frac 1 2 = ln ( 2 ) k e displaystyle = frac ln(2) k_ text e Elimination rate constant The rate at which a drug is removed from the body. 0.0578 h−1 k e displaystyle k_ text e = ln ( 2 ) t 1 2 = C L V d displaystyle = frac ln(2) t_ frac 1 2 = frac CL V_ text d Infusion rate
k in displaystyle k_ text in = C ss ⋅ C L displaystyle =C_ text ss cdot CL Area under the curve The integral of the concentration-time curve (after a single dose or in steady state). 1,320 mg/L·h A U C 0 − ∞ displaystyle AUC_ 0-infty = ∫ 0 ∞ C d t displaystyle =int _ 0 ^ infty C,operatorname d t A U C τ , ss displaystyle AUC_ tau , text ss = ∫ t t + τ C d t displaystyle =int _ t ^ t+tau C,operatorname d t Clearance The volume of plasma cleared of the drug per unit time. 0.38 L/h C L displaystyle CL = V d ⋅ k e = D A U C displaystyle =V_ text d cdot k_ text e = frac D AUC Bioavailability The systemically available fraction of a drug. 0.8 f displaystyle f = A U C po ⋅ D iv A U C iv ⋅ D po displaystyle = frac AUC_ text po cdot D_ text iv AUC_ text iv cdot D_ text po Fluctuation Peak trough fluctuation within one dosing interval at steady state. 41.8 % % P T F displaystyle %PTF = C max , ss − C min , ss C av , ss ⋅ 100 displaystyle = frac C_ text max , text ss -C_ text min , text ss C_ text av , text ss cdot 100 where C av , ss = 1 τ A U C τ , ss displaystyle C_ text av , text ss = frac 1 tau AUC_ tau , text ss [ v t e ] In pharmacokinetics, steady state refers to the situation where the overall intake of a drug is fairly in dynamic equilibrium with its elimination. In practice, it is generally considered that steady state is reached when a time of 4 to 5 times the half-life for a drug after regular dosing is started. The following graph depicts a typical time course of drug plasma concentration and illustrates main pharmacokinetic metrics: The time course of drug plasma concentrations over 96 hours following oral administrations every 24 hours. Note that the AUC in steady state equals AUC∞ after the first dose. Pharmacokinetic models[edit] Pharmacokinetic modelling is performed by noncompartmental or compartmental methods. Noncompartmental methods estimate the exposure to a drug by estimating the area under the curve of a concentration-time graph. Compartmental methods estimate the concentration-time graph using kinetic models. Noncompartmental methods are often more versatile in that they do not assume any specific compartmental model and produce accurate results also acceptable for bioequivalence studies. The final outcome of the transformations that a drug undergoes in an organism and the rules that determine this fate depend on a number of interrelated factors. A number of functional models have been developed in order to simplify the study of pharmacokinetics. These models are based on a consideration of an organism as a number of related compartments. The simplest idea is to think of an organism as only one homogenous compartment. This monocompartmental model presupposes that blood plasma concentrations of the drug are a true reflection of the drug’s concentration in other fluids or tissues and that the elimination of the drug is directly proportional to the drug’s concentration in the organism (first order kinetics). However, these models do not always truly reflect the real situation within an organism. For example, not all body tissues have the same blood supply, so the distribution of the drug will be slower in these tissues than in others with a better blood supply. In addition, there are some tissues (such as the brain tissue) that present a real barrier to the distribution of drugs, that can be breached with greater or lesser ease depending on the drug’s characteristics. If these relative conditions for the different tissue types are considered along with the rate of elimination, the organism can be considered to be acting like two compartments: one that we can call the central compartment that has a more rapid distribution, comprising organs and systems with a well-developed blood supply; and a peripheral compartment made up of organs with a lower blood flow. Other tissues, such as the brain, can occupy a variable position depending on a drug’s ability to cross the barrier that separates the organ from the blood supply. This two compartment model will vary depending on which compartment elimination occurs in. The most common situation is that elimination occurs in the central compartment as the liver and kidneys are organs with a good blood supply. However, in some situations it may be that elimination occurs in the peripheral compartment or even in both. This can mean that there are three possible variations in the two compartment model, which still do not cover all possibilities.[6] This model may not be applicable in situations where some of the enzymes responsible for metabolizing the drug become saturated, or where an active elimination mechanism is present that is independent of the drug's plasma concentration. In the real world each tissue will have its own distribution characteristics and none of them will be strictly linear. If we label the drug’s volume of distribution within the organism VdF and its volume of distribution in a tissue VdT the former will be described by an equation that takes into account all the tissues that act in different ways, that is: V d F = V d T 1 + V d T 2 + V d T 3 + ⋯ + V d T n displaystyle Vd_ F =Vd_ T1 +Vd_ T2 +Vd_ T3 +cdots +Vd_ Tn , This represents the multi-compartment model with a number of curves that express complicated equations in order to obtain an overall curve. A number of computer programs have been developed to plot these equations.[6] However complicated and precise this model may be, it still does not truly represent reality despite the effort involved in obtaining various distribution values for a drug. This is because the concept of distribution volume is a relative concept that is not a true reflection of reality. The choice of model therefore comes down to deciding which one offers the lowest margin of error for the drug involved. Graph representing the monocompartmental action model. Noncompartmental analysis[edit]
Noncompartmental PK analysis is highly dependent on estimation of
total drug exposure. Total drug exposure is most often estimated by
area under the curve (AUC) methods, with the trapezoidal rule
(numerical integration) the most common method. Due to the dependence
on the length of x in the trapezoidal rule, the area estimation is
highly dependent on the blood/plasma sampling schedule. That is, the
closer time points are, the closer the trapezoids reflect the actual
shape of the concentration-time curve.
Compartmental analysis[edit]
Compartmental PK analysis uses kinetic models to describe and predict
the concentration-time curve. PK compartmental models are often
similar to kinetic models used in other scientific disciplines such as
chemical kinetics and thermodynamics. The advantage of compartmental
over some noncompartmental analyses is the ability to predict the
concentration at any time. The disadvantage is the difficulty in
developing and validating the proper model. Compartment-free modelling
based on curve stripping does not suffer this limitation. The simplest
PK compartmental model is the one-compartmental PK model with IV bolus
administration and first-order elimination. The most complex PK models
(called
C = C initial × e − k el × t displaystyle C=C_ text initial times e^ -k_ text el times t Multi-compartmental models[edit] Graphs for absorption and elimination for a non-linear pharmacokinetic model. The graph for the non-linear relationship between the various factors is represented by a curve; the relationships between the factors can then be found by calculating the dimensions of different areas under the curve. The models used in non-linear pharmacokinetics are largely based on Michaelis–Menten kinetics. A reaction’s factors of non-linearity include the following: Multiphasic absorption:
Plasma drug concentration vs time after an IV dose Alpha phase: An initial phase of rapid decrease in plasma concentration. The decrease is primarily attributed to drug distribution from the central compartment (circulation) into the peripheral compartments (body tissues). This phase ends when a pseudo-equilibrium of drug concentration is established between the central and peripheral compartments. Beta phase: A phase of gradual decrease in plasma concentration after the alpha phase. The decrease is primarily attributed to drug metabolism and excretion.[7] Additional phases (gamma, delta, etc.) are sometimes seen.[8] A drug’s characteristics make a clear distinction between tissues with high and low blood flow. Enzymatic saturation: When the dose of a drug whose elimination depends on biotransformation is increased above a certain threshold the enzymes responsible for its metabolism become saturated. The drug’s plasma concentration will then increase disproportionately and its elimination will no longer be constant. Induction or enzymatic inhibition: Some drugs have the capacity to inhibit or stimulate their own metabolism, in negative or positive feedback reactions. As occurs with fluvoxamine, fluoxetine and phenytoin. As larger doses of these pharmaceuticals are administered the plasma concentrations of the unmetabolized drug increases and the elimination half-life increases. It is therefore necessary to adjust the dose or other treatment parameters when a high dosage is required. The kidneys can also establish active elimination mechanisms for some drugs, independent of plasma concentrations. It can therefore be seen that non-linearity can occur because of
reasons that affect the entire pharmacokinetic sequence: absorption,
distribution, metabolism and elimination.
Variable volume in time models[edit]
B A = [ A B C ] P ⋅ D I V [ A B C ] I V ⋅ D P displaystyle B_ A = frac [ABC]_ P cdot D_ IV [ABC]_ IV cdot D_ P B R = [ A B C ] A ⋅ dose B [ A B C ] B ⋅ dose A displaystyle mathit B _ R = frac [ABC]_ A cdot text dose _ B [ABC]_ B cdot text dose _ A Once a drug’s bioavailability has been established it is possible to
calculate the changes that need to be made to its dosage in order to
reach the required blood plasma levels.
D e = B ⋅ D a displaystyle De=Bcdot Da, ; where De is the effective dose, B bioavailability and Da the administered dose. Therefore, if a drug has a bioavailability of 0.8 (or 80%) and it is administered in a dose of 100 mg, the equation will demonstrate the following: De = 0.8 × 100 mg = 80 mg That is the 100 mg administered represents a blood plasma concentration of 80 mg that has the capacity to have a pharmaceutical effect. Different forms of tablets, which will have different pharmacokinetic behaviours after their administration. This concept depends on a series of factors inherent to each drug, such as:[12] Pharmaceutical form Chemical form Route of administration Stability Metabolism These concepts, which are discussed in detail in their respective titled articles, can be mathematically quantified and integrated to obtain an overall mathematical equation: D e = Q ⋅ D a ⋅ B displaystyle De=Qcdot Dacdot B, where Q is the drug’s purity.[12] V a = D a ⋅ B ⋅ Q τ displaystyle Va= frac Dacdot Bcdot Q tau where V a displaystyle Va is the drug’s rate of administration and τ displaystyle tau is the rate at which the absorbed drug reaches the circulatory system. Finally, using the Henderson-Hasselbalch equation, and knowing the drug’s p K a displaystyle pKa, (pH at which there is an equilibrium between its ionized and non ionized molecules), it is possible to calculate the non ionized concentration of the drug and therefore the concentration that will be subject to absorption: p H = p K a + log B A displaystyle pH=pKa+log frac B A When two drugs have the same bioavailability, they are said to be biological equivalents or bioequivalents. This concept of bioequivalence is important because it is currently used as a yardstick in the authorization of generic drugs in many countries. LADME[edit] Main article: ADME A number of phases occur once the drug enters into contact with the organism, these are described using the acronym LADME: Liberation of the active substance from the delivery system,
Absorption of the active substance by the organism,
Distribution through the blood plasma and different body tissues,
Some textbooks combine the first two phases as the drug is often
administered in an active form, which means that there is no
liberation phase. Others include a phase that combines distribution,
metabolism and excretion into a disposition phase. Other authors
include the drug’s toxicological aspect in what is known as ADME-Tox
or ADMET.
Each of the phases is subject to physico-chemical interactions between
a drug and an organism, which can be expressed mathematically.
Narrow therapeutic range (difference between toxic and therapeutic concentrations) High toxicity High risk to life.
Medications for which monitoring is recommended
+ Phenytoin + Carbamazepine + Valproic acid + Lamotrigine + Ethosuximide + Phenobarbital + Primidone Cardioactive medication + Digoxin + Lidocaine Immunosuppressor medication + Ciclosporin + Tacrolimus + Sirolimus + Everolimus + Mycophenolate
+ Gentamicin + Tobramycin + Amikacin + Vancomycin
+ Theophylline
+ Methotrexate + 5-Fluorouracil + Irinotecan * Antiviral (HIV) medication + Efavirenz + Tenofovir + Ritonavir Coagulation factors + Factor VIII, + Factor IX, + Factor VIIa, + Factor XI Ecotoxicology[edit]
Idiosyncratic drug reaction Drug interaction Patlak plot Pharmacometrics Pharmacy Bioequivalence Generic drugs Physiologically based pharmacokinetic modelling Plateau principle Toxicokinetics References[edit] ^ Pharmacokinetics. (2006). In Mosby's Dictionary of Medicine, Nursing
& Health Professions. Philadelphia, PA: Elsevier Health Sciences.
Retrieved December 11, 2008, from
http://www.credoreference.com/entry/6686418
^ Knights K, Bryant B (2002).
External links[edit] This article's use of external links may not follow's policies or guidelines. Please improve this article by removing excessive or inappropriate external links, and converting useful links where appropriate into footnote references. (May 2016) (Learn how and when to remove this template message) Software[edit] Noncompartmental Freeware: bear and PK for R Commercial: MLAB, EquivTest, Kinetica, MATLAB/SimBiology, PKMP,Phoenix/WinNonlin, PK Solutions, RapidNCA. Compartment based Freeware: ADAPT, Boomer (GUI), SBPKPD.org (Systems Biology Driven
Physiologically based Freeware: MCSim Commercial: acslX, Cloe PK, GastroPlus, MATLAB/SimBiology, PK-Sim, ProcessDB, Simcyp, Entelos PhysioLab Phoenix/WinNonlin, ADME Workbench. Population PK Freeware: WinBUGS, ADAPT, S-ADAPT / SADAPT-TRAN, Boomer, PKBugs, Pmetrics for R. Commercial: Kinetica, MATLAB/SimBiology, Monolix, NONMEM, Phoenix/NLME, PopKinetics for SAAM II, USC*PACK, Navigator Workbench. Simulation All model based software above. Freeware: COPASI, Berkeley Madonna, MEGen. Educational centres[edit] Global centres with the highest profiles for providing in-depth training include the Universities of Buffalo, Florida, Gothenburg, Leiden, Otago, San Francisco, Beijing, Tokyo, Uppsala, Washington, Manchester, Monash University, and University of Sheffield.[1] v t e Concepts in pharmacology Pharmacokinetics (L)ADME: (Liberation)
Absorption
Distribution
Metabolism
Loading dose
Compartment Bioequivalence Bioavailability Onset of action Biological half-life Mean residence time Plasma protein binding
Pharmacodynamics Mechanism of action
Antimicrobial pharmacodynamics: Minimum inhibitory concentration
(Bacteriostatic)
Agonism and antagonism Agonist: Inverse agonist Irreversible agonist Partial agonist Superagonist Physiological agonist Antagonist: Competitive antagonist Irreversible antagonist Physiological antagonist Other: Binding Affinity Binding selectivity Functional selectivity Other Drug tolerance: Tachyphylaxis Drug resistance:
Drug discovery strategies Classical pharmacology Reverse pharmacology Related fields/subfields Pharmacogenetics Pharmacogenomics
Authority control NDL: 01033752 ^ Tucker GT (June 2012). "Research priorities in pharmacokinetics". British Journal of Clinical Pharmacology. 73 (6): 924–6. doi:10.1111/j.1365-2125.2012.04238.x. PMC 3391520 . PMID |